A preliminary study on the enhancement of the osteointegration of a novel synthetic hydroxyapatite scaffold in vivo.
Synthetic hydroxyapatite, a bioactive calcium phosphate, is clinically used as a bone replacement bioceramic because of its similarity in composition to bone mineral, biocompatibility, and osteoconductive nature. The aim of this study was to evaluate the bioactivity of a novel synthetic porous hydroxyapatite (PHA) in vivo in rabbit and to investigate the enhancement of its bioactivity and osteointegration. In the investigation reported here, insulin-like growth factor-I (IGF-I) has been used to enhance the bioactivity of PHA. Cylindrical PHA implants with or without IGF-I were implanted bilaterally in rabbit femurs. Fluorochrome bone markers were administered at 7-day intervals. The implants with the attached bone were retrieved at postmortem, 1 and 3 weeks after implantation, for histological and histomorphometric analysis. Undecalcified sections stained with toluidine blue showed new bone formation. Mineralization of the new bone formed in the interface, surrounding trabecular bone, and within the pores of the implants was studied. Lamellar bone mineral apposition rate (MAR) was assessed and compared among treatment groups, sham, PHA alone, and PHA with IGF-I (500 ng/implant), by fluorochrome label incorporation using UVL microscopy. We report for the first time, that the supplementation of PHA implants with IGF-I significantly increased new bone formation and MAR (6.58 +/- 0.08 microm/day) compared with implantation of PHA alone (4.08 +/- 0.05 microm/day) or sham operation (3.11 +/- 0.12 microm/day). These results suggest that synthetic PHA might provide a delivery system for bioactive agents to accelerate bone healing in orthopedic procedures.
Damien
Elsie
E
Department of Histopathology, University College London, Royal Free Campus, University of London, United Kingdom. edamien@rfc.ucl.ac.uk
Hing
Karin
K
Saeed
Suhur
S
Revell
Peter A
PA
D000818:Animals; D001672:Biocompatible Materials / Q000378:metabolism*; D018786:Bone Substitutes / Q000378:metabolism*; D001842:Bone and Bones / Q000166:cytology / Q000187:drug effects / Q000378:metabolism*; D017886:Durapatite / Q000378:metabolism*; D005260:Female; D017102:Fracture Healing / Q000187:drug effects; D006133:Growth Substances / Q000494:pharmacology; D007334:Insulin-Like Growth Factor I / Q000494:pharmacology; D011817:Rabbits
D001672:Biocompatible Materials; D018786:Bone Substitutes; D006133:Growth Substances; D007334:Insulin-Like Growth Factor I; D017886:Durapatite